GlaxoSmithKline Plc - Product Pipeline Review - 2016

  • ID: 3641084
  • Company Profile
  • 406 pages
  • Global Markets Direct
  • GlaxoSmithKline PLC
1 of 4
GlaxoSmithKline Plc - Product Pipeline Review - 2016

Summary

‘GlaxoSmithKline Plc - Product Pipeline Review - 2016’, provides an overview of the GlaxoSmithKline Plc’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by GlaxoSmithKline Plc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of GlaxoSmithKline Plc
- The report provides overview of GlaxoSmithKline Plc including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses GlaxoSmithKline Plc’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features GlaxoSmithKline Plc’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate GlaxoSmithKline Plc’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for GlaxoSmithKline Plc
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding GlaxoSmithKline Plc’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

GlaxoSmithKline Plc Snapshot

GlaxoSmithKline Plc Overview

Key Information

Key Facts

GlaxoSmithKline Plc - Research and Development Overview

Key Therapeutic Areas

GlaxoSmithKline Plc - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Combination Treatment Modalities

Pipeline Products - Partnered Products

Pipeline Products - Out-Licensed Products

GlaxoSmithKline Plc - Pipeline Products Glance

GlaxoSmithKline Plc - Late Stage Pipeline Products

GlaxoSmithKline Plc - Clinical Stage Pipeline Products

GlaxoSmithKline Plc - Early Stage Pipeline Products

GlaxoSmithKline Plc - Unknown Stage Pipeline Products

GlaxoSmithKline Plc - Drug Profiles

gepirone hydrochloride ER

GSK-257049

GSK-2696273

mepolizumab

melanoma lysate vaccine

(fluticasone furoate + umeclidinium bromide + vilanterol trifenatate)

(fluticasone furoate + vilanterol trifenatate)

(measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine

albiglutide

ambrisentan

AS15 + recMAGE-A3

belimumab

bupropion hydrochloride ER

Ebola [Zaire] vaccine

fluticasone furoate

GSK-1437173A

inotersen sodium

KD-295

losmapimod

meningococcal [serotype B] vaccine

retosiban

tafenoquine succinate

vilanterol trifenatate

zanamivir

(batefenterol succinate + fluticasone furoate)

(fluticasone furoate + levocabastine hydrochloride)

alitretinoin

batefenterol

CAD-106

camicinal

dabrafenib mesylate + panitumumab + trametinib dimethyl sulfoxide

danirixin

daprodustat

fluticasone furoate + umeclidinium bromide

gepotidacin mesylate

group B Streptococcus (trivalent) vaccine

GSK-2189242A

GSK-2231392A

GSK-2245035

GSK-2256098

GSK-2269557

GSK-2302032A

GSK-2315698 + GSK-2398852

GSK-2330672

GSK-2339345

GSK-239512

GSK-2586881

GSK-2696274

GSK-2696275

GSK-2789869A

GSK-2830930A

GSK-2838504A

GSK-2862277

GSK-3003891A

GSK-3196165

GSK-3277511A

GSK-692342

GSK-933776

GVXNSD-133

hepatitis C vaccine 1

malaria vaccine

mapatumumab

maribavir

meningococcal [serotypes A, B, C, W-135, Y] (pentavalent) vaccine

otelixizumab

respiratory syncytial virus vaccine

rilapladib

Streptococcal pneumonia vaccine 3

umeclidinium bromide

GSK-2302025A

GSK-2636771

GSK-525762

HIV [strains C1086 + TV1] (bivalent) vaccine

pazopanib hydrochloride + pembrolizumab

TDEN-PIV

(amlodipine besylate + rosuvastatin calcium)

(candesartan cilexetil + hydrochlorothiazide)

(diphtheria + pertussis (acellular) + tetanus) vaccine

1790GAHB

EcoXyn-4V

epelsiban besylate

FP-1039

GSK-1940029

GSK-2130579A

GSK-2241658A

GSK-2256294

GSK-2330811

GSK-2618960

GSK-2646264

GSK-2654909A

GSK-2654911A

GSK-2789868A

GSK-2798745

GSK-2800528

GSK-2816126

GSK-2831781

GSK-2849330

GSK-2857916

GSK-2878175

GSK-2879552

GSK-2881078

GSK-2981278

GSK-2981710

GSK-2982772

GSK-3008348

GSK-3117391

GSK-3174998

GSK-3206640A

GSK-3206641A

GSK-3389245A

hepatitis C vaccine 2

HIV vaccine 1

HIV vaccine 5

IMP-731

influenza [strain A/H5N1] vaccine

influenza vaccine 2

montelukast sodium

omipalisib

oxytocin

RSV-001

Staphylococcus aureus vaccine

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine

BLyS-gel

Cellular Immunotherapy to Target Flt3L for Autoimmune Myocarditis

Gene Therapy to Activate Lysyl Hydroxylase-3 for Recessive Dystrophic Epidermolysis Bullosa

GSK-030

GSK-1795091

GSK-2041706

GSK-214096

GSK-2225745

GSK-2394002

GSK-2656157

GSK-2795039

GSK-2820151

GSK-3039294

GSK-3277509A

GSK-3277510A

GSK-3326595

GSK-3359609

GSK-6288B

GSK-8853

GSKJ-4

GW-610742

HIV vaccine 2

influenza vaccine

marburg vaccine

meningococcal vaccine 2

Monoclonal Antibody Conjugate for Oncology

raxibacumab

Recombinant Protein to Antagonize CCR8 for Graft Versus Host Disease and Multiple Sclerosis

Small Molecule 1 for Malaria

Small Molecule 1 to Inhibit Histone Methyltransferases for Cancer

Small Molecule 2 for Malaria

Small Molecule 2 for Tuberculosis

Small Molecule 2 to Inhibit Histone Methyltransferases for Cancer

Small Molecule 3 to Inhibit Histone Methyltransferases for Cancer

Small Molecule for Hypertension and Insulin Resistance

Small Molecule to Activate AMPK for Type 2 Diabetes

Small Molecule to Agonize S1P1 for Multiple Sclerosis

Small Molecules to Inhibit InhA for Tuberculosis

Small Molecules to Inhibit ROR gamma-t for Multiple Sclerosis and Rheumatoid Arthritis

staphylococci aureus vaccine

Streptococcal pneumonia vaccine

TC-2153

tuberculosis vaccine

Vaccine for Alzheimer's Disease

Vaccine for Cancer

bacterial vaccine

bacterial vaccine 2

Drug for Chronic Liver Disease

Drugs to Antagonize T-Cell Receptor for Oncology

Drugs to Inhibit Kynurenine 3-Monooxygenase for Acute Pancreatitis

GSK-137647A

GSK-343

GSK-5959

GSKJ-1

Proteins for Musculoskeletal Disorders

Pseudomonas aeruginosa vaccine

Small Molecule for Tuberculosis

Small Molecule to Antagonize FFA4 for Undisclosed Indication

Small Molecule to Inhibit Histone Deacetylases for Oncology

Small Molecules for HIV-1 Infection

Small Molecules for Tuberculosis

Small Molecules for Undisclosed Indication

Small Molecules to Antagonize Folate Receptor for Tuberculosis

Small Molecules to Inhibit ATPase family AAA Domain-Containing Protein 2 for Oncology

Small Molecules to Inhibit Falcipain for Malaria

Small Molecules to Inhibit Leucyl-tRNA Synthetase for Tuberculosis

Small Molecules to Inhibit RNA Polymerase for Hepatitis C

(paratyphoid + typhoid) vaccine

GlaxoSmithKline Plc - Pipeline Analysis

GlaxoSmithKline Plc - Pipeline Products by Target

GlaxoSmithKline Plc - Pipeline Products by Route of Administration

GlaxoSmithKline Plc - Pipeline Products by Molecule Type

GlaxoSmithKline Plc - Pipeline Products by Mechanism of Action

GlaxoSmithKline Plc - Recent Pipeline Updates

GlaxoSmithKline Plc - Dormant Projects

GlaxoSmithKline Plc - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

GlaxoSmithKline Plc - Company Statement

GlaxoSmithKline Plc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

GlaxoSmithKline Plc - Key Manufacturing Facilities

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

GlaxoSmithKline Plc, Key Information

GlaxoSmithKline Plc, Key Facts

GlaxoSmithKline Plc - Pipeline by Indication, 2016

GlaxoSmithKline Plc - Pipeline by Stage of Development, 2016

GlaxoSmithKline Plc - Monotherapy Products in Pipeline, 2016

GlaxoSmithKline Plc - Combination Treatment Modalities in Pipeline, 2016

GlaxoSmithKline Plc - Partnered Products in Pipeline, 2016

GlaxoSmithKline Plc - Partnered Products/ Combination Treatment Modalities, 2016

GlaxoSmithKline Plc - Out-Licensed Products in Pipeline, 2016

GlaxoSmithKline Plc - Out-Licensed Products/ Combination Treatment Modalities, 2016

GlaxoSmithKline Plc - Pre-Registration, 2016

GlaxoSmithKline Plc - Filing rejected/Withdrawn, 2016

GlaxoSmithKline Plc - Phase III, 2016

GlaxoSmithKline Plc - Phase II, 2016

GlaxoSmithKline Plc - Phase I, 2016

GlaxoSmithKline Plc - IND/CTA Filed, 2016

GlaxoSmithKline Plc - Preclinical, 2016

GlaxoSmithKline Plc - Discovery, 2016

GlaxoSmithKline Plc - Unknown, 2016

GlaxoSmithKline Plc - Pipeline by Target, 2016

GlaxoSmithKline Plc - Pipeline by Route of Administration, 2016

GlaxoSmithKline Plc - Pipeline by Molecule Type, 2016

GlaxoSmithKline Plc - Pipeline Products by Mechanism of Action, 2016

GlaxoSmithKline Plc - Recent Pipeline Updates, 2016

GlaxoSmithKline Plc - Dormant Developmental Projects,2016

GlaxoSmithKline Plc - Discontinued Pipeline Products, 2016

GlaxoSmithKline Plc, Other Locations

GlaxoSmithKline Plc, Subsidiaries

GlaxoSmithKline Plc, Key Manufacturing Facilities

List of Figures

GlaxoSmithKline Plc - Pipeline by Top 10 Indication, 2016

GlaxoSmithKline Plc - Pipeline by Stage of Development, 2016

GlaxoSmithKline Plc - Monotherapy Products in Pipeline, 2016

GlaxoSmithKline Plc - Combination Treatment Modalities in Pipeline, 2016

GlaxoSmithKline Plc - Partnered Products in Pipeline, 2016

GlaxoSmithKline Plc - Out-Licensed Products in Pipeline, 2016

GlaxoSmithKline Plc - Pipeline by Top 10 Target, 2016

GlaxoSmithKline Plc - Pipeline by Route of Administration, 2016

GlaxoSmithKline Plc - Pipeline by Top 10 Molecule Type, 2016

GlaxoSmithKline Plc - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll